Data published today at the Global Congress on Prostate Cancer demonstrates the potential of the MDxH SelectMDx urine-based test to reduce the need for expensive and complex MRI, as well as to help guide physicians in deciding for and against prostate biopsies in clinical practice. These positive results reinforce our view of SelectMDx as a substantial value driver for MDxHealth. We reiterate our OUTPERFORM recommendation and €9 / share target price.
